Faeth Therapeutics, Inc. (FTH) stock
FTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.72−0.32 (-3.54%)
Close on Nov 18, 2026Market cap $225.33MP/E –Yield –
Faeth Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Faeth Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$33.86M. For fiscal 2025 it was -$20.47M. The highest annual figure on record is -$18.91M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$20.47M | – |
| FY2024 | Dec 31, 2024 | -$24.82M | – |
| FY2023 | Dec 31, 2023 | -$32.20M | – |
| FY2022 | Dec 31, 2022 | -$39.35M | – |
| FY2021 | Dec 31, 2021 | -$32.29M | – |
| FY2020 | Dec 31, 2020 | -$18.91M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.67M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.74M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.86M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.59M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.93M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.09M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.79M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.47M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.65M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.16M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.66M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.49M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.89M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.57M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.05M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.95M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.77M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.40M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.97M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.66M | – |
| Q1 FY2021 | Mar 31, 2021 | -$11.25M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.00M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.63M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.77M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.51M | – |
See a number that looks wrong?